Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | MALT1 | Q9UDY8 | 17/20 | 0.40 |
| ▸ | BIRC3 | Q13489 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17292958 | 0.84 | MALT1 (0.47) | KDM4ENPC1HPGDRAB9ALMNA | |
| SCHEMBL18863029 | 0.83 | KDM4E (0.45) | KDM4ENPC1HPGDRAB9ALMNA | |
| SCHEMBL18787643 | 0.80 | KDM4E (0.43) | KDM4ENPC1HPGDRAB9ALMNA | |
| SCHEMBL18787821 | 0.80 | MALT1 (0.55) | KDM4ENPC1HPGDRAB9ALMNA | |
| SCHEMBL17293012 | 0.80 | MALT1 (0.55) | KDM4ENPC1HPGDRAB9ALMNA | |
| SCHEMBL17293010 | 0.80 | MALT1 (0.55) | KDM4ENPC1HPGDRAB9ALMNA | |
| SCHEMBL18787713 | 0.78 | MALT1 (0.57) | KDM4ENPC1HPGDRAB9ALMNA | |
| SCHEMBL18787657 | 0.78 | MALT1 (0.52) | KDM4ENPC1HPGDRAB9ALMNA | |
| SCHEMBL17293052 | 0.78 | MALT1 (0.52) | KDM4ENPC1HPGDRAB9ALMNA | |
| SCHEMBL17293051 | 0.78 | MALT1 (0.52) | KDM4ENPC1HPGDRAB9ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10442808-B2 | Pyrazolo pyrimidine derivatives and their use as MALT1 inhbitors | NOVARTIS AG (CH) | 2019-10-15 | — | — | US | disclosed |
| US-20180030061-A1 | NOVEL PYRAZOLO PYRIMIDINE DERIVATIVES AND THEIR USE AS MALT1 INHBITORS | NOVARTIS AG (CH) | 2018-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180030061-A1 | NOVEL PYRAZOLO PYRIMIDINE DERIVATIVES AND THEIR USE AS MALT1 INHBITORS | MMEL1, MALT1, FBP1 | KDM4E 3265/4885NPC1 2168/4885HPGD 2368/4885 |
| US-10442808-B2 | Pyrazolo pyrimidine derivatives and their use as MALT1 inhbitors | FBP1, MMEL1, MALT1 | KDM4E 3589/4885NPC1 2196/4885HPGD 1918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.